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 ﾠ
Current in vitro hematopoiesis models fail to demonstrate the cellular 
diversity and complex functions of living bone marrow and hence, most 
translational studies relevant to the hematologic system are conducted in live 
animals.  Here, we describe a method for fabricating a “bone marrow-on-a-chip” 
that permits culture of a living marrow with a functional hematopoietic niche in 
vitro by first engineering new bone in vivo, removing it whole, and perfusing it 
with culture medium in a microfluidic device.  The engineered marrow retains 
hematopoietic stem and progenitor cells in normal in vivo-like proportions for at 
least one week in culture.  The device models organ-level marrow toxicity 
responses and protective effects of radiation countermeasure drugs, whereas 
conventional bone marrow culture methods do not.  This biomimetic microdevice 
offers a new approach for analysis of drug responses and toxicities in bone 
marrow, as well as study of hematopoiesis and hematologic diseases in vitro. 
____________________________________________________________________________  
The bone marrow microenvironment contains a complex set of cellular, chemical, 
structural and physical cues necessary to maintain the viability and function of the 
hematopoietic system
1-5.  This hematopoietic niche regulates hematopoietic stem cells 
(HSCs), facilitating a delicate balance between self-renewal and differentiation into 
progenitor cells that produce all mature blood cell types
4,5.  Engineering an artificial 
bone marrow that reconstitutes natural marrow structure and function, and that can be 
maintained in culture, could be a powerful platform to study hematopoiesis and test new 
therapeutics.  It has proven difficult, however, to recreate the complex bone marrow 
microenvironment needed to support the formation and maintenance of a complete, 
functional hematopoietic niche in vitro
6-9.  Although various in vitro culture systems have (Revised NMETH-A19608) 	 ﾠ
been developed to maintain and expand hematopoietic stem and progenitor cells
6-11, 
there is currently no method to recreate or study the intact bone marrow 
microenvironment in vitro.  Therefore, studies on hematopoiesis commonly rely on 
animal models to ensure the presence of an intact bone marrow microenvironment that 
enables normal physiologic marrow responses
12-15.  Furthermore, although it has been 
reported that bone marrow can be engineered in vivo
16-19, no method exists to culture 
engineered bone marrow in vitro.  To bridge the functional gap between in vivo and in 
vitro systems, we developed a method to produce a “bone marrow-on-a-chip” culture 
system that contains artificial bone and a living marrow, which is first generated in mice, 
and then explanted whole and maintained in vitro within a microfluidic device.   
 
RESULTS 
In vivo engineering of bone marrow 
Tissue engineering methods have been used to induce formation of new bone 
with a central marrow compartment in vivo
18-21.  To explore the possibility of engineering 
an artificial bone marrow that can be explanted whole, we microfabricated a poly-
dimethylsiloxane (PDMS) device with a central cylindrical cavity (1 mm high x 4 mm 
diameter) with openings at both ends (Fig. 1a).  We filled the hollow compartment with a 
type I collagen gel containing bone-inducing demineralized bone powder (DBP) and 
bone morphogenetic proteins (BMP2 and BMP4)
20-22, and implanted it subcutaneously 
on the back of a mouse (Supplementary Fig. 1).  Our goal was to engineer bone that 
would fill the cylindrical space within the implanted device so that it could be easily 
removed whole and inserted into a microfluidic system containing a similarly shaped (Revised NMETH-A19608) 	 ﾠ
chamber for in vitro culture (Fig. 1 a,b).  These initial studies resulted in the creation of 
new bone encasing a marrow compartment that formed within the PDMS device 4 to 8 
weeks after subcutaneous implantation.  Histological analysis revealed that the marrow 
was largely inhabited by adipocytes and exhibited a low level of hematopoietic cell 
contribution, even 8 weeks after implantation (Fig. 1c), as previously noted by others 
using similar tissue engineering approaches with bone-inducing materials
19-21.   
The presence of large numbers of adipocytes in bone marrow can inhibit 
hematopoiesis
23.  To reduce adipocyte content in the marrow, we sealed the top of 
central cavity in the implanted device by adding a solid layer of PDMS to restrict access 
of cells or soluble factors from the overlying adipocyte-rich hypodermis to the bone-
inducing materials, while maintaining accessibility to the underlying muscle tissue 
through the lower opening (Fig. 1a, Supplementary Fig. 1).  Subcutaneous 
implantation of this improved PDMS device resulted in the formation of a cylindrical disk 
of white, boney tissue containing a central blood-filled marrow over a period of 8 weeks 
(Fig. 1b, Supplementary Fig.  2).  Histological analysis confirmed the presence of a 
shell of cortical bone of relatively uniform thickness surrounding a marrow dominated by 
hematopoietic cells, containing only rare adipocytes (Fig. 1c).  Comparison of 
histological sections of the engineered bone marrow (eBM) to sections from an intact 
femur confirmed that the morphology of the eBM was nearly identical to that of natural 
bone marrow (Fig. 1c).  
Micro-computed tomographic (micro-CT) analysis of the eBM demonstrated that 
the newly formed cortical shell of bone also contained an ordered internal trabecular 
network that closely resembles the intricate architecture found in normal adult mouse (Revised NMETH-A19608) 	 ﾠ
vertebrae (Supplementary Fig. 3 ), and which is known to be supportive of HSCs
24 
(Fig. 1d).  Compositional analysis using energy dispersive x-ray spectroscopy (EDS) 
also showed that the calcium and phosphorus content of the eBM are indistinguishable 
from natural trabecular bone (Supplementary Fig.  3). 
Characterization of engineered bone marrow 
Interactions between CXCL12 expressed on the surfaces of various cell types in 
the bone marrow (e.g., osteoblasts
25, perivascular endothelial and perivascular stromal 
cells
26) and its cognate receptor CXCR4 on the surfaces of HSCs and hematopoietic 
progenitor cells are critical for the recruitment, retention and maintenance of HSCs
26-28. 
Immunohistochemical analysis confirmed that both of these key hematopoietic 
regulators are expressed in their normal positions in the eBM: CXCL12 localized to cells 
lining the inner surface of the bone and blood vessels, while CXCR4 was expressed by 
clusters of lymphoid cells in the endosteal and perivascular niches (Fig. 2 a-d).  We 
also confirmed that key hematopoietic niche cells
29 including perivascular Nestin+ cells 
and Leptin receptor+ cells as well as CD31+ vascular endothelial cells reside in their 
normal positions (Supplementary Fig. 4).  Together, these data demonstrate that our 
modified bone tissue engineering strategy produced a cortical shell of bone with an 
internal network of trabecular bone and a normal appearing marrow filling its central 
space.  The presence of key cellular and molecular components of the hematopoietic 
niche suggests that the cellular content of the eBM closely resembles that of natural 
bone.  
To rigorously characterize the hematopoietic content of the engineered marrow, 
cells were harvested from the eBM immediately after surgical removal and analyzed by (Revised NMETH-A19608) 	 ﾠ
flow cytometry.  The cellular components of the marrow contained within the eBM were 
compared to hematopoietic populations isolated from femur bone marrow and 
peripheral blood from the same mice (Fig. 2 e,f).  Devices harvested 4 and 8 weeks 
after implantation contained all blood cell types, including HSCs (Lin
-Sca1
+cKit
+CD34
+/-, 
Lin
-Sca1
+cKit
+CD150
+/-CD48
-/+), and hematopoietic progenitor cells identified by four 
different marker sets (Lin
-Sca1
+, Lin
-cKit
+, Lin
-CD34
+, Lin
-CD135
+), as well as mature 
erythrocytes (Ter119), lymphocytes (T cells, CD45
+CD3
+; B cells, CD45
+CD19
+) and 
myeloid cells (CD45
+Mac1
+/-Gr1
+/-).  The eBM harvested 4 weeks after implantation did 
not appear to be fully developed, as indicated by a lower proportion of HSCs and 
hematopoietic progenitor cells, compared to normal marrow (Fig. 2 g,h).  However, 
cells harvested from the eBM 8 weeks after implantation exhibited a completely normal 
distribution of HSCs, hematopoietic progenitors, and differentiated blood cells from all 
lineages that was nearly identical to that displayed by natural bone marrow (Fig. 2 g,h 
and Supplementary Fig.  5,  6). Together, these data demonstrate that the eBM 
consists of a cylindrical disk of cortical and trabecular bone (Supplementary Fig. 3) 
containing marrow that also has nearly identical hematopoietic cell composition as 
natural bone marrow. 
In vitro culture of engineered bone marrow 
To determine whether the eBM can maintain a functional hematopoietic system 
in vitro, the eBM formed 8 weeks after implantation was surgically removed from the 
mouse, punctured in multiple places with a surgical needle to permit fluid access, and 
cultured in another clear PDMS microfluidic device containing a similarly shaped, 
cylindrical central chamber that is separated from overlying and underlying microfluidic (Revised NMETH-A19608) 	 ﾠ
channels by porous membranes (Fig. 1 a,b).  To maintain cellular viability of the eBM, 
culture medium was perfused through the top and bottom channels using a syringe 
pump at a rate (1 µL/min) optimized to maintain cellular viability (Supplementary Fig.  
7) once being inserted into the central chamber and the surrounding porous membranes 
and microchannel layers were attached.  The eBMs were cultured in vitro for 4 or 7 days 
within the bone marrow chip microsystem (Fig. 1b), which covers a time period that is 
commonly used to test for drug efficacies and toxicities in vitro
30,31. The cultured bone 
and marrow retained their morphology during this time, including the distribution of 
CXCL 12-expressing stromal cells (Supplementary Fig.  8).  Stroma-supported culture 
systems represent the current benchmark for maintaining survival of HSCs and 
hematopoietic progenitor cells in vitro
7,32.  Thus, we used flow cytometric analysis to 
compare the hematopoietic cellular composition of the cultured bone marrow-on-a-chip 
to that of marrow isolated from mouse femur cultured for the same amount of time on a 
stromal ‘feeder’ cell layer (Supplementary Fig.  9).  Because past work has shown that 
addition of cytokines is required to maintain or expand HSCs and their progenitors
6,7, 
and serum can suppress the marrow reconstituting activity of HSCs
33, the stroma-
supported cultures were maintained in serum-free medium supplemented with cytokines 
(mSCF, mIL-11, mFLt-3 ligand, and hLDL) that have been shown by others to more 
efficiently maintain and expand both HSCs and hematopoietic progenitor cell 
populations in vitro
34.  Our analysis revealed that there was no significant difference in 
cell viability after 4 or 7 days of culture in the microfluidic eBM device compared to the 
static stroma-supported culture (Supplementary Fig.  10).  However, bone marrow 
cultured on  stroma exhibited a significant decrease (P < 0.0005) in the number of long-(Revised NMETH-A19608) 	 ﾠ
term HSCs (Lin
-CD150
+ CD48
- cells) and a concomitant increase (p < 0.0005) in 
hematopoietic progenitor cells (Lin
-CD34
+, Lin
-Sca1
+, Lin
-cKit
+) relative to cells freshly 
isolated from natural mouse bone marrow (Fig. 3 a,b).  Thus, the long-term HSCs, 
which are the only cells capable of long-term self-renewal and multi-lineage potential, 
appear to be differentiating into more specialized progenitor cells in the static stroma-
supported cultures system, as previously reported
6-9.  In contrast, the number and 
distribution of HSCs and hematopoietic progenitor cells in the eBM cultured for up to 7 
days on-chip were maintained in similar proportions to freshly harvested bone marrow 
(Fig. 3a).  Importantly, the bone marrow-on-a-chip enabled maintenance of a 
significantly higher proportion of long-term HSCs, while more effectively maintaining the 
distribution of mature blood cells compared to the stroma-supported cultures (Fig. 3b).  
Interestingly, while the proportions of hematopoietic cells were retained over this culture 
period, there was no significant difference in the number or viability of cells cultured on-
chip for 7 days compared to 4 days, hence the HSCs and hematopoietic progenitor cells 
appeared to remain relatively quiescent in the marrow-on-a-chip microdevice.  
Moreover, while addition of exogenous (and expensive) cytokines, including mSCF, 
mIL-11, mFLt-3 ligand, and hLDL are critical for maintenance of these cell populations 
in conventional stroma-supported cultures
6,7,34, their removal from culture medium had 
little effect on the distribution of HSCs and hematopoietic progenitors in the cultured 
eBM (Fig. 3d).  Thus, the eBM contains a functional hematopoietic niche that behaves 
in an autonomous fashion to support the continued survival of these critical blood-
forming stem and progenitor cells in vitro.  Taken together, these data suggest that the 
bone marrow-on-a-chip contains a functional hematopoietic microenvironment that (Revised NMETH-A19608) 	 ﾠ
supports and regulates blood cell populations in normal proportions that can be 
maintained for at least one week under microfluidic flow in vitro, even in the absence of 
exogenous cytokines.   
To confirm that the HSCs and hematopoietic progenitor cells retained in the 
cultured bone marrow-on-a-chip remain truly functional, we evaluated their self-renewal 
and differentiation capabilities by testing engraftment and hematopoietic reconstitution 
potential following transplantation into lethally-irradiated, syngeneic, recipient mice.  
Cells within the marrow compartments of eBMs that were formed in GFP-expressing 
animals and cultured on-chip for 4 days were harvested and transplanted into γ-
irradiated mice; results were compared to irradiated mice that were transplanted with 
cells freshly harvested bone marrow from mouse femur.  Total engraftment was 
assessed in the peripheral blood of recipient mice 6 and 16 weeks after transplantation 
to confirm the presence of functional short- and long-term HSCs, respectively.  Cells 
harvested from the eBM following 4 days in culture on-chip successfully engrafted the 
mice at a similar rate as freshly isolated, uncultured bone marrow (Fig. 3e), and 
repopulated all differentiated blood cell lineages (Fig. 3f) showing 70% and 85% 
engraftment by 6 and 16 weeks after transplantation, respectively.  These data confirm 
that the hematopoietic compartment of the eBM retains fully functional, self-renewing, 
multi-potent HSCs after being cultured in the microfluidic bone marrow chip for 4 days in 
vitro. 
In vitro model for radiation toxicity 
The functionality and organ-level responsiveness of the bone marrow-on-a-chip 
were tested by exposing the eBM to varying doses of γ-radiation to determine whether (Revised NMETH-A19608) 	 ﾠ
this method can be used as an in vitro model for radiation toxicity, which currently can 
only be studied in live animals.  Live mice, eBMs cultured on-chip, and marrow cells 
maintained in stroma-supported culture were exposed to 1 and 4 Gray (Gy) doses of γ-
radiation that have been previously shown to produce marrow toxicity in mice
35,
 and 
maintained in culture.  When measured 4 days after radiation exposure, we detected a 
statistically significant, radiation dose-dependent decrease in the proportion of HSCs 
(Fig. 4a), hematopoietic progenitors (Fig. 4 b,c), lymphoid cells (Fig. 4d), and myeloid 
cells (Fig. 4e), which closely mimics what is observed in the bone marrow of live, 
irradiated mice.  Interestingly, the proportion of HSCs (Lin
-Sca1
+cKit
+) or progenitors 
(Lin
-CD34
+) observed in eBM after exposure to 1 and 4 Gy doses of γ-radiation were 
nearly identical to the proportions measured in whole marrow from live mice that 
underwent similar irradiation.  In contrast, the proportion of HSCs and progenitors were 
significantly (P < 0.05) lower in the stroma-supported culture after 4 Gy irradiation 
compared to 1 Gy irradiation.  Various types of marrow cells (HSCs, progenitors, 
lymphoid and myeloid cells) cultured on stroma also exhibited suppressed responses, 
and all were significantly (P < 0.05) more resistant to the effects of radiation toxicity (Fig 
4 a-e, Supplementary Fig.  11).   
To further evaluate the functional relevance and power of our system, we tested 
the effects of administering granulocyte colony-stimulating factor (G-CSF), which has 
been shown to accelerate recovery and prevent potentially lethal bone marrow failure 
following radiation-exposure in vivo
36.  When G-CSF was added to the eBM cultured on-
chip one day after exposure to γ-radiation, samples analyzed three days later 
demonstrated a significant increase in the total number of HSCs (Lin
-Sca1
+cKit
+) and (Revised NMETH-A19608) 	 ﾠ
hematopoietic progenitor cells (Lin
-cKit
+, Lin
-CD34
+) compared to untreated bone 
marrow chips that were similarly irradiated (Fig. 4f).  These findings suggest that G-
CSF induced proliferation of HSCs and hematopoietic progenitor cells in the bone 
marrow chip in vitro, as previously reported in vivo
36.  These data clearly demonstrate 
that the bone marrow-on-a-chip faithfully mimics the natural physiological response of 
living bone marrow to clinically relevant doses of γ-radiation and to a validated radiation 
countermeasure drug (G-CSF), whereas conventional stroma-supported cultures do 
not.   
 
DISCUSSION 
Our bone marrow-on-a-chip fabrication strategy provides an important proof-of-concept 
for the creation of an organ-on-chip device that reconstitutes and sustains an intact, 
functional, living bone marrow when cultured in vitro.  This strategy differs significantly 
from conventional tissue engineering approaches in which materials or living cells are 
implanted in vivo without geometric constraint, and without any intent of removing the 
newly formed organ and maintaining its viability ex vivo. While we regenerate the 
complex structural, physical and cellular microenvironment of whole bone marrow by 
employing in vivo tissue engineering techniques, we then leverage microfluidic 
strategies to deliver nutrients, chemicals and other soluble signals in a fashion that 
supports the continued viability and function of this engineered organ in vitro.  This also 
differs from most organ-on-chip approaches that use microengineering and microfluidics 
approaches to model tissue architecture, cell-cell relationships, chemical gradients and (Revised NMETH-A19608) 	 ﾠ
the mechanical microenvironment, and then inhabit the devices with cultured cell lines 
or isolated stem cells
37.   
Our in vivo engineering approach enabled us to reconstitute hematopoietic niche 
physiology and restore complex tissue-level functions of natural bone marrow.   The 
eBM autonomously produces the factors necessary to support the maintenance and 
function of the hematopoietic system in vitro, which offers a major practical advantage 
over existing culture systems in that expensive growth supplements can be removed 
from the culture medium or greatly reduced.  Another advantage is that the bone 
marrow-on-a-chip supports hematopoietic stem and progenitor cells in normal in vivo-
like proportions relative to the other hematopoietic cell populations and maintains their 
spatial positions within a fully formed 3D bone marrow niche in vitro. These features of 
the bone marrow-on-a-chip are likely key to its ability to preserve complex functionalities 
of the whole organ that cannot be replicated by conventional stroma-supported cultures. 
Importantly, the use of microfluidics also enables analysis of responses under flow, 
which is important for both regulation of marrow physiology
5,6,10,38,39 and study of 
pharmacokinetic and pharmacodynamic (PK/PD) behaviors of drugs that are critical for 
evaluation of their clinical behavior. 
The eBM cultured on-chip mimics complex tissue-level responses to radiation 
toxicity normally only observed in vivo, and to a therapeutic countermeasure agent (G-
CSF) that is known to accelerate recovery from radiation-induced toxicity in patients
40.  
Thus, this biomimetic microsystem could serve as a valuable in vitro replacement for 
whole animals in the testing and development of drugs and other medical 
countermeasures that might protect against radiation poisoning in the future. (Revised NMETH-A19608) 	 ﾠ
Apparently, the completeness of our organ mimic permits us to recapitulate the 
physiologic responses of the whole hematopoietic niche to clinically relevant cues (e.g., 
cytokines, drugs, radiation) whereas conventional cell cultures do not.  This finding 
underscores the novelty of maintaining a functional marrow containing multiple 
components of the hematopoietic niche in vitro, rather than merely culturing particular 
hematopoietic cell types.    
The bone marrow-on-a-chip provides an interesting alternative to animal models, 
because it offers the unique ability to manipulate individual hematopoietic cell 
populations (e.g., genetically or using drugs), or to insert other cell types (e.g., tumor 
cells) in vitro, before analyzing the response of the intact marrow to relevant clinical 
challenges, including radiation or pharmaceuticals.  It also might be possible to 
generate human bone marrow models; for example, an eBM could be engineered in 
immunocompromised mice (e.g., NOD.Cg-Prkdc
scid Il2rg
tm1Wjl/Sz; NSG) that have their 
endogenous marrow cells replaced with human hematopoietic cells.   
The ability to produce trabecular bone with architectural and compositional 
properties similar to natural bone offers a way to produce bones of pre-defined size and 
shape, and it could represent a new method to study bone biology, remodeling, and 
bone pathophysiology in vitro.  Therefore, the bone marrow-on-a-chip is a powerful 
method to accelerate discovery and development in a wide range of biomedical fields 
ranging from hematology, oncology, and drug discovery to tissue engineering.  
   (Revised NMETH-A19608) 	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FIGURE LEGENDS 
Fig. 1.  In vivo bone marrow engineering.  (a) Workflow to generate a bone 
marrow-on-a-chip system in which engineered bone marrow (eBM) is formed in a 
PDMS device in vivo and is then cultured in a microfluidic system.  (b) Photographs 
showing the PDMS device containing bone-inducing materials in its central cylindrical 
chamber before implantation (top panel), the formed white cylindrical bone with pink 
marrow visible within eBM 8 weeks after implantation (middle panel), and the bone 
marrow chip microdevice used to culture the eBM in vitro (lower panel) (bar, 2 mm).  (c) 
Low (left) and high (right) magnification views of histological H&E-stained sections of 
the eBM formed in the PDMS device with two opening (top), one lower opening (middle) 
at 8 weeks following implantation compared with a cross-section of bone marrow within 
the normal adult mouse femur (bottom) (bars, 50 and 500 µm for low and high 
magnification views, respectively).  (d) Three-dimensional reconstruction of micro-
computed tomography (micro-CT) data from eBM 8 weeks after implantation (average 
bone volume was 2.95 ± 0.25 mm
3; n=3).  
Fig. 2.  Localization of cytokines and hematopoietic cell composition of the 
engineered bone marrow.  (a-d) Immunohistochemical analysis of ligand-receptor 
pair, CXCL12 and CXCR4, in eBM compared to mBM (uncultured, mouse femur bone 
marrow).  Anti-CXCL12 staining of the eBM (a) and mBM (b).  Anti-CXCR4, staining of   
eBM (c) and  mBM (d).  Images are taken at 63X magnification (bars, 25 µm).  (e) Flow 
cytometric analysis of HSCs and hematopoietic progenitor cells within the Lin negative 
cell subpopulation isolated from mBM and eBM isolated 8 weeks after subcutaneous 
implantation.  Numbers inside individual gates indicate the proportion of these cells as a (Revised NMETH-A19608) 	 ﾠ
percentage of the total cell population isolated from whole bone marrow.  (g) 
Distribution of HSCs (Lin
-Sca1
+cKit
+, red) and hematopoietic progenitor cells (Lin
-Sca1
+, 
cyan; Lin
-cKit
+, purple; Lin
-CD34
+, green; Lin
-CD135
+, blue) as quantified by flow 
cytometric analysis of mBM (n = 6), eBM at 4 (n = 5) or 8 weeks (n = 5) after 
implantation, or mouse peripheral blood (mPB) (n = 1) that underwent erythrocyte lysis 
to facilitate detection of rare HSCs.  Flow cytometry plots (f) and distribution (h) of 
matured, lineage-restricted cell types including erythrocytes (Ter119
+, blue), myeloid 
cells (CD45
+Mac1
+, orange; CD45
+Gr1
+, green; CD45
+Mac1
+Gr1
+, purple), B cells 
(CD45
+CD19
+, cyan) and T cells (CD45
+CD3
+, red) in mBM (n = 6), eBM 4 wk (n = 5), 
eBM 8 wk (n = 5) and intact mPB (n = 1).  Error bars represent s.e.m.  
Fig. 3.  In vitro microfluidic culture of eBM within the bone marrow-on-a-
chip. (a) Abundance of HSCs (Lin
-Sca1
+cKit
+ cells, red) and hematopoietic progenitor 
cells (Lin
-Sca1
+, cyan; Lin
-cKit
+, purple; Lin
-CD34
+, green; Lin
-CD135
+, blue) in mBM, 
femur bone marrow cultured for 4 and 7 days a stroma-supported culture system (mBM 
D4, mBM D7), fresh uncultured eBM, and eBM after 4 and 7 days of culture on-chip 
(eBM D4, eBM D7) (n = 7 for all conditions).  (b) Abundance of long-term HSCs (Lin
-
CD150
+CD48
-) present in mBM, mBM  after 4 and 7 days in stroma-supported culture, 
eBM and eBM after culture for 4 and 7 days (n = 7).  Statistical analysis was conducted 
using two-tailed T-test assuming independent samples with equal variance.  (c) 
Abundance of erythrocytes (Ter119
+, blue), myeloid cells (CD45
+Mac1
+/-Gr1
+/-, green), 
B cells (CD45
+CD19
+, purple) and T cells (CD45
+CD3
+, orange) in the mBM and eBM 
populations at the time of isolation compared to 4 and 7 days of culture (n = 6).  (d) 
Abundance of HSCs and hematopoietic progenitor cells from fresh, uncultured eBM (Revised NMETH-A19608) 	 ﾠ
compared to 4 and 7 days of culture with and without supplemental cytokines (SCF, IL-
11, Flt-3, LDL) (n = 6).  (e) The extent of bone marrow engraftment in lethally irradiated 
mice transplanted with 2.5 x 10
5 GFP
+ cells from uncultured mBM or isolated from the 
eBM following 4 days of in vitro culture on-chip.  Engraftment is presented as 
percentage of GFP+ cells in the lymphoid population (CD45
+) of peripheral blood 
measured 6 weeks and 16 weeks after transplantation to confirm retention of functional 
hematopoietic progenitor cells and HSCs, respectively (n = 3).  (f) Distribution of 
differentiated blood cells within the engrafted CD45
+ population from mBM and eBM D4 
transplants at 6 and 16 weeks after intravenous injection into lethally irradiated mice.  
Differentiated cell types include T cells (CD45
+CD3
+, purple), B cells (CD45
+CD19
+, 
green) and myeloid cells (CD45
+Mac1
+, blue; CD45
+Gr1
+, red) (n = 3).  Error bars 
represent s.e.m.  
Fig. 4. Radiation toxicity of the bone marrow-on-a-chip.  (a-d) Effects of γ-
radiation (0, 1 or 4 Gy) on the abundance of (a) HSCs (Lin
-Sca1
+cKit
+), (b,c) 
hematopoietic progenitors (Lin
-CD34
+, Lin
-cKit
+), (d) lymphoid cells (CD45
+CD3
+, 
CD45
+CD19
+) and (e) myeloid cells (CD45
+Mac1
+/-Gr1
+/-) within bone marrow of freshly 
isolated from femurs of living mice (in vivo), eBM cultured on-chip for 4 days (eBM), or 4 
day old stroma-supported cultures (Dish) n = 5).  (f) Effect of G-CSF  on the abundance 
of HSCs (Lin
-Sca1
+cKit
+ cells, black) and hematopoietic progenitor cells (Lin
-cKit
+, 
white; Lin
-CD34
+, gray) in eBM cultured on-chip for 4 days (n = 5).  Statistical analysis 
was conducted using two-tailed T-test assuming independent samples with equal 
variance.. Error bars represent s.e.m.; P-values above individual bars represent (Revised NMETH-A19608) 	 ﾠ
comparisons between in vivo and experimental samples; brackets represent 
comparisons between experimental samples.   (Revised NMETH-A19608) 	 ﾠ
ONLINE METHODS  
Animals.  CD1 mice were purchased from Charles River Laboratories and 
C57BL/6 mice and C57BL/6-Tg(UBC-GFP)30Scha/J mice were from Jackson 
Laboratories.  All animal studies were reviewed and approved by the Animal Care and 
Use Committee of Children’s Hospital Boston.  For both implantation of devices and 
transplant experiments, no randomization or blinding was completed.  All transplanted 
mice and those implanted with devices were equivalent (age, sex, strain). 
Bone-inducing materials.  Demineralized bone powder (DBP) was prepared 
from femurs harvested from CD-1 mice
18.  The femurs were washed in sterile water, 
extracted with absolute ethanol, and dehydrated with ether.  The bones were crushed 
with a mortar and pestle and demineralized in 0.5 N HCl (50 mL/g) for 3 hours at room 
temperature.  After demineralization, DBP was washed with sterile water, extracted with 
absolute ethanol, dehydrated with ether, and was passed through a sieve with 250 µm 
pores.  3 mg DBP mixed with 30 µL solution of type I collagen gel (3 mg/mL, Cellmatrix 
Type I-A, Nitta Gelatin Inc.), 100 ng BMP2 (Alpha Diagnostic Intl. Inc.), and 100 ng 
BMP4 (Alpha Diagnostic Intl. Inc.) was placed in the central cylindrical cavity (1 mm 
high x 4 mm diameter) of a device (1 mm high x 8 mm diameter) (Fig. 1A, B) which was 
fabricated from poly-dimethylsiloxane (PDMS) formed from prepolymer (Sylgard 184, 
Dow Corning) at a ratio of 10:1 base to curing agent and using biopsy punches (Miltex, 
Inc.).  To seal the top of the central cylindrical cavity, a solid layer of PDMS (0.5 mm 
thick) and the device were bonded together using a plasma etcher (SPI Plasma-Perp ΙΙ, 
Structure Probe, Inc.) in air for 30 seconds.    (Revised NMETH-A19608) 	 ﾠ
Implantation of bone inducing materials.  The PDMS devices filled with the 
bone-inducing materials were implanted subcutaneously on the backs of 8- to 12-week-
old CD-1 mice or C57BL/6-Tg(UBC-GFP)30Scha/J mice, and harvested 4 or 8 weeks 
after implantation (Supplementary Fig. S1).  Because implantation of devices was 
completed in all animals procured or bred, a randomization procedure was not 
performed. The PDMS device with two openings permitted access between the bone-
inducing materials and both the underlying muscle and overlying skin (Fig. 1A and 
Supplementary Fig. S1).  The PDMS device with a single lower opening only permitted 
access to the muscle.  
Histology and Immunohistochemistry.  Engineered bone marrow (eBM) 
harvested from mice 8 weeks after implantation, and femurs from the same mice, were 
collected and fixed in 4% paraformaldehyde at 4°C for 24 hours.  Tissues were 
transferred into 70% ethanol and stored at room temperature until processed. Tissues 
were embedded in paraffin and sectioned for subsequent staining hematoxalin and 
eosin (H&E) staining, immunohistochemistry using anti-CXCL12 (SDF-1 beta; 
eBioscience, #14-7991-83) or anti-CXCR4 (UMB2; Novus Biologicals LLC, #NBP1-
95362) polyclonal antibodies, followed by anti-rabbit IgG conjugated to HRP (Vector 
Laboratories).  Slides were counterstained with hematoxylin.  Tissues were also 
embedded in Tissue-Tek O.C.T. (Sakura Finetek USA, Inc.) and sectioned for 
subsequent immunofluorescence analysis using anti-CD31 (Abcom, #ab28364), anti-
Nestin (Abcam, #ab6142), or anti-Leptin receptor (Abbiotec, #250739), followed by anti-
rabbit IgG conjugated to Alexa Fluor 488 (Life Technologies, #A11034) or anti-mouse 
IgG conjugated to Alexa Fluor 488 (Life Technologies, #A21202).  (Revised NMETH-A19608) 	 ﾠ
Flow cytometry.  To evaluate the distribution of the various hematopoietic cell 
populations, flow cytometric analysis was performed using 5-laser-Fortessa flow 
cytometer (Becton Dickinson).  Cell types were evaluated based on expression of 
surface antigens that are characteristic for HSCs, long-term HSCs, hematopoietic 
progenitor cells and multiple differentiated blood cell lineages.  The differential 
distribution was evaluated based on percentage of whole bone marrow.  Because the 
HSCs and hematopoietic progenitor cell populations represent a small percentage of 
the total, representative flow cytometry plots are shown after excluding mature lineage-
restricted (Lin
-) cells.  The numbers shown on the FACS plots indicate the percent 
contribution relative to the whole bone marrow population.  To harvest bone marrow 
cells, the eBM was removed from the PDMS devices, cut into small pieces and digested 
using 1 mg/mL collagenase (Roche) for 30 min.  Bone marrow cells harvested from 
eBM and normal mouse femur were stained in cold PBS containing 3% FBS and 0.05% 
sodium azide for 30 minutes with antibodies directed against 1) eFluor 450 
hematopoietic lineage cocktail (1:5, eBioscience, #88-7772-72), APC Sca1 (1:333, 
eBioscience, #17-5981-82, clone D7), APC-eFluor780 cKit (1:160, eBioscience, #47-
1172-82, clone ACK2), FITC CD34 (1:50, eBioscience, #11-0341-82, clone RAM34) or 
APC CD34 (1:10, eBioscience, #50-0341-82, clone RAM34), and PE CD135 (1:20, 
eBioscience, 12-1351-82, clone A2F10) to identify HSCs (Lin
-Sca1
+cKit
+), progenitor 
cells (Lin
-Sca1
+, Lin
-cKit
+, Lin
-CD34
+, Lin
-CD135
+), 2) lineage cocktail (1:5, eBioscience, 
#88-7772-72), PE CD150 (1:40, eBioscience, #12-1501-82, clone 9D1), and APC CD48 
(1:160, eBioscience, #17-0481-82, clone HM48-1) to identify long-term HSCs (Lin
-
CD150
+CD48
-), or 3) APC-eFluor780 Ter119 (1:40, eBioscience, #47-5921-82, clone (Revised NMETH-A19608) 	 ﾠ
TER-119), Pacific Blue CD45 (1:200, eBioscience, #48-0451-82, clone 30-F11), APC-
Cy7 CD3 (1:20, BD Pharmingen, #560590, clone 17A2), APC CD19 (1:80, BD 
Pharmingen, #550991, clone 1D2), APC-Cy7 Mac1 (1:160, eBioscience, #47-0112-82, 
clone M1/70), and APC Gr1 (1:160, eBioscience, #17-5931-82, clone RB6-8C5) to 
identify erythrocytes (Ter119), leukocytes (CD45), B cells (CD19), T cells (CD3), and 
myeloid cells (Mac1 and Gr1).  Cellular viability was evaluated using propidium iodide 
(25 ng/mL, Millipore).  
In vitro microfluidic culture on-chip.  The cylindrical eBM was removed from 
the PDMS device, pierced multiple (4-6) times with a surgical needle (32 gauge), and 
cultured in a similarly shaped central chamber within a microfluidic chip device (Fig. 1A, 
B) that was separated from overlying and underlying microfluidic channels (200 µm 
high) by porous PDMS membranes (20 µm thick with 100 µm pores).  The microfluidic 
channels were molded against master molds made by standard photolithography using 
the negative-photoresist SU-8 (MicroChem Co.).  PDMS membranes were made by 
spin-coating a PDMS layer on a silanized glass slide at 1500 rpm for 60 seconds and 
then curing in an 80
oC oven for at least 2 hours.  An array of 100 µm pores with a 100 
µm pitch was made on a PDMS membrane using a laser cutter (Versal Laser VL-300, 
Universal Laser Systems, Inc.).  Microfluidic channel layers and porous PDMS 
membranes were bonded together using a plasma etcher in air for 30 seconds.  To 
allow introduction of solution into the channels, access holes were punched through the 
top channel layer with a 2 mm biopsy punch and the inlets and the outlets were 
connected with tubes (i.d.=1/32 inch).  The microfluidic device was oxidized using a 
plasma etcher in air for 10 min to make the PDMS surface hydrophilic. The eBM was (Revised NMETH-A19608) 	 ﾠ
inserted into the central chamber (which was bonded to the bottom channel layer) 
before attachment of the top channel layer.  The microfluidic device was placed 
between two acrylic plates (3 mm diameter) made by a laser cutter and immobilized 
using screws (Fig. 1B)  To maintain cellular viability of the eBM, culture medium (SFEM 
basal medium, StemCell Technologies) containing cytokines
33 (50 ng/mL mouse SCF, 
100 ng/mL mouse IL-11, 100 ng/mL mouse FLt-3, and 20 µg/mL human LDL, StemCell 
Technologies) was perfused through the top and bottom channels (1 µL/min, 0.005 
dyn/cm
2) using a syringe pump (BS-8000, Braintree Scientific, Inc.).   
Stroma-supported bone marrow cell culture.  Bone marrow stromal cells were 
harvested from 8- to 12-week-old C57BL/6 mice, re-suspended in DMEM medium 
(Gibco) containing 20% FBS (Gibco), GlutaMAX (Gibco), and 100 units/mL penicillin-
streptomycin (Gibco), and cultured in the same medium on tissue culture plates 
(Falcon), changing the medium every other day to create stromal feeder layers.  After 
the adherent monolayer became established (about 3 weeks), the cells were irradiated 
with 12 Gy.  Bone marrow cells harvested from femurs of C57BL/6-Tg(UBC-
GFP)30Scha/J mice were cultured on this  bone marrow stromal cell layer using the 
same culture medium as use in the microfluidic culture.     
Bone marrow transplantation.  Bone marrow transplantation was performed on 
8-week-old C57BL/6 mice exposed to two doses of radiation measuring 6 Gy separated 
by 2-3 hours. Because these mice were purchased from a vendor and randomized upon 
arrival, a randomization procedure was not conducted.  The bone marrow cells were 
harvested from femurs of C57BL/6-Tg(UBC-GFP)30Scha/J mice or from eBM produced 
in similar GFP-labeled mice after 4 days of microfluidic culture.  2.5 × 10
5 bone marrow (Revised NMETH-A19608) 	 ﾠ
cells were delivered by intravenous (i.v.) tail vein injection within 12 hours of lethal 
irradiation.  Engraftment was measured 6 weeks and 16 weeks after transplant using 
retro-orbital bleeds and flow cytometric analyses.   
Micro-computed tomographic (micro-CT) analysis.  eBM harvested from mice 
4 and 8 weeks after device implantation were fixed for 48 hours in 4% 
paraformaldehyde and stored in 70% ethanol at 4°C.  Vertebrae harvested from the 
same mice immediately device removal were handled similarly.  Both the eBM and 
vertebrae were imaged (in 70% ethanol) with an XRA-002 X-Tek MicroCT system. X-ray 
transmission images were acquired at 55kV and 200µA and the 3D reconstructions 
were performed using CT-Pro (Nikon Metrology); surface renderings were generated 
using VGStudio Max. 
Compositional backscattered scanning electron (BSE) micrographs and 
elemental mapping.  eBM and vertebrae harvested and fixed as described for micro-
CT were serially dehydrated into 100% ethanol and then embedded in Spurr’s resin and 
sectioned at the desired imaging plane using a slow speed diamond saw.  The resulting 
sections were polished with silicon carbide papers down to P1200, sputter coated with 
gold and examined using a Tescan Vega-3 scanning electron microscope equipped with 
a Bruker X-Flash 530 energy dispersive spectrometer (EDS).  All EDS spectra and 
elemental maps were acquired at 20keV accelerator voltage.  For calculating elemental 
composition of both the sectioned implant and vertebra samples, 10 point spectra from 
the surface of each sample were acquired and the percent phosphorus and calcium 
content was determined by averaging the obtained values ± s.e.m. (Revised NMETH-A19608) 	 ﾠ
γ−Radiation.  Freshly harvested eBM made in C57BL/6-Tg(UBC-GFP)30Scha/J 
(Jackson Laboratories) mice, 1 x 10
7 mouse femur bone marrow cells maintained in 
stroma-supported culture, and 8 week old C57BL/6-Tg(UBC-GFP)30Scha/J were 
exposed to one does of gamma-irradiation (Cs-137), 1Gy or 4Gy.  Ninety-six hours after 
irradiation, marrow from the eBM cultured on-chip, bone marrow in stroma-supported 
culture, and bone marrow from the femurs of live mice were collected for flow cytometric 
analysis.  500 U/mL granulocyte colony-stimulating factor (G-CSF, Sigma-Aldrich) was 
added in the culture medium containing cytokines 24 hours after exposure to gamma-
irradiation.  After 72 hours in culture on-chip with G-CSF, marrow from the eBM was 
collected for flow cytometric analysis.  
Statistics.  Sample size for in vitro and in vivo experiments was determined 
based on a minimum of n = 3 biological replicates.  Statistical differences were analyzed 
by Student’s T-test.  All statistical evaluation was conducted using a two-tailed T-test, 
assuming independent samples of normal distribution with equal variance.  P < 0.05 
were deemed statistically significant; all error bars indicate standard error of the mean. 
 
Editorial	 ﾠsummary:	 ﾠ
Bone	 ﾠmarrow	 ﾠformed	 ﾠin	 ﾠa	 ﾠcylindrical	 ﾠPDMS	 ﾠdevice	 ﾠimplanted	 ﾠin	 ﾠa	 ﾠmouse	 ﾠcan	 ﾠbe	 ﾠsurgically	 ﾠremoved	 ﾠand	 ﾠ
cultured	 ﾠfor	 ﾠa	 ﾠweek	 ﾠin	 ﾠvitro	 ﾠwithout	 ﾠlosing	 ﾠany	 ﾠof	 ﾠthe	 ﾠhallmarks	 ﾠof	 ﾠin	 ﾠvivo	 ﾠbone	 ﾠmarrow	 ﾠniches.	 ﾠ	 ﾠ
 
 